• Application of the broad acting HTR antagonist methiothepin

  2025-02-17

  

  Application of the broad-acting 5-HTR antagonist methiothepin (Bard et al., 1996, Hoyer et al., 1994, Peroutka, 1990) converted the TBS-induced response of both thalamocortical and intracortical A1 synapses from LTP to LTD, an effect that was mimicked by the selective 5-HT2R antagonist ketanserin (L

• Mechanisms implicated in antinociception by A R

  2025-02-17

  

  Mechanisms implicated in antinociception by A3R agonists in neuropathic pain are summarized in Box 3. Cellular transduction mechanisms for A3Rs include inhibition of cyclic AMP, PKA via Gαi, interactions with PLC/IP3/DAG and signaling via Gαi and Gαq, and interactions with PI3K/MEK/ERK via βγ subuni

• PAN induced nephrosis was accompanied

  2025-02-17

  

  PAN-induced nephrosis was accompanied by loss of body weight, decrease of food intake, increase in urine volume and increases in triglycerides and cholesterol levels, which have been reported previously (Natori et al., 1996). Except for urine volume, each one of these measures was improved by A-306

• br Acknowledgements br Introduction Autoantibodies directed

  2025-02-17

  

  Acknowledgements Introduction Autoantibodies directed at neurotransmitter receptors and ion channels are pathogenic and/or biomarkers in several autoimmune neurological diseases [1]. For example, autoantibodies directed against voltage-gated potassium channels, the P/Q-type (α1A) voltage-gated

• The anorexic effect observed when AR is infused

  2025-02-17

  

  The anorexic effect observed when AR231630 is infused into the VTA could be the result of the DA release inhibition, as previously described [11]. However, there is also a hedonic aspect in feeding that possibly involves dopaminergic mechanisms of reward. Helm et al. showed a functional link betwee

• During the year study period of

  2025-02-17

  

  During the 4-year study period, 19.9% of men in the dutasteride group developed prostate cancer as compared to 25.1% in the placebo group, which represents an absolute risk Bioactive plant extract of 5.1% for men taking dutasteride (Pe weighed against the prospect of undesirable sexual side effects

• Previous studies have demonstrated ATR inhibition is

  2025-02-17

  

  Previous studies have demonstrated ATR inhibition is effective for treating cancers combining with chemotherapies in lung adenocarcinoma, gastric cancer, HER2 positive breast cancer and chronic lymphocytic leukemia tenofovir alafenamide to enhance chemotherapy sensitivity [[16], [17], [18],[20], [2

• Currently NSAIDs which achieve antineoplastic actions mainly

  2025-02-15

  

  Currently, NSAIDs which achieve antineoplastic actions mainly through apoptosis are emerging choice in chemotherapy. Their antineoplastic effects were demonstrated before in tumor-bearing models [5], [6], [7]. Through in vitro cell models, we identified an indomethacin-activation of ceramide/PP2A/Ak

• br Introduction O Dowd et al identified

  2025-02-15

  

  Introduction O’Dowd et al. identified a gene very similar to angiotensin type-1 receptor in 1993 (O’Dowd et al., 1993). The specific selective ligand of this receptor called APJ receptor was determined by Tatemoto et al. in 1998 as apelin (Tatemoto et al., 1998). The high expression of apelin and

• The alamarBlue test revealed that recombinant apelin

  2025-02-15

  

  The alamarBlue test revealed that recombinant apelin led to an increase in basal and IGF1- and FHS-induced ovarian cell proliferation. Apelin increased ERK1/2 and Akt protein expression, but cell proliferation returned to control levels in the presence of kinase inhibitors. This suggests that the pr

• To the best of our knowledge only cases

  2025-02-15

  

  To the best of our knowledge, only 3 cases of an E196K mutation have been described since it was first identified in 2000 [15], [16], [17], although 5 cases, accounting for 1.1% of all genetic TSE cases, were reported with no precise data on the clinical phenotypes in the EUROCJD collaborative surve

• No starting dose adjustment is needed for mild or moderate

  2025-02-15

  

  No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad

• Recently the FDA approved the

  2025-02-15

  

  Recently, the FDA approved the first blood-based test for the detection of EGFR mutations in non-small cell lung cancer patients (http://www.fda.gov) (Voelker, 2016). This allows detection of specific, recurrent mutations, which can help the selection of the patients that could benefit from Erlotini

• A number of studies indicate the involvement of the classica

  2025-02-15

  

  A number of studies indicate the involvement of the classical AR or a splice variant that translocate to the membrane, via a palmitoylation mechanism, similar to ERα (Acconcia et al., 2005, Acconcia et al., 2004, Acconcia et al., 2003), since AR equally contains the required nine amino NLG919 palmi

• br Introduction There are greater than five million American

  2025-02-15

  

  Introduction There are greater than five million Americans living with Alzheimer's dementia and more than 35 million people worldwide [1], and without a way to stop or slow the progression, there will be nearly a tripling of individuals affected by 2050 (13.8 million) [1]. The urgency to develop

16573 records 9/1105 page Previous Next First page 上5页 678910 下5页 Last page